|Bid||63.490 x 1900|
|Ask||63.500 x 1000|
|Day's Range||63.410 - 64.110|
|52 Week Range||58.290 - 66.800|
|PE Ratio (TTM)||34.39|
|Dividend & Yield||1.88 (2.85%)|
|1y Target Est||N/A|
Analysts at Citi hold a bullish rating on Merck & Co., Inc. (NYSE: MRK ). The firm's Andrew Baum upgraded Merck's stock from Neutral to Buy "for the first time," with a price target boosted from ...
Keytruda is an immunotherapy drug used in cancer treatments. Citi increased its peak Keytruda sales forecast on the drug to $16 billion from $9 billion.
After months of headlines about astronomical drug prices, a funny thing’s happening — drug costs are plummeting.
The pharmaceutical industry puts the cost of bringing a medicine from invention to pharmacy shelves at $2.7 billion. A new paper says it is 'just' $648 million. Unfortunately for pharmaceutical investors and people fighting to control drug prices, alike, the new number doesn’t stand up scrutiny.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Merck & Co., Inc. a score of 47. Our analysis is based on comparing Merck & Co., Inc. with the following peers – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ... Read more (Read more...)
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $11.76 billion.
Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion. The slowdown in Gilead’s HCV business is starting to come to an end. The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Merck & Co., Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives ...
Merck & Co Inc said on Wednesday it will not seek regulatory approval for its experimental cholesterol drug, anacetrapib, as the clinical profile of the treatment does not support regulatory filings. In August, a large study on anacetrapib found that the treatment cut the risk of heart attack and death by a modest 9 percent, while causing a build up of the drug in fat tissue, leaving its commercial future uncertain. The treatment is part of a class known as CETP inhibitors designed to raise HDL, the so-called good cholesterol.
Ever since scientists began decoding the human genome in 1990, doctors have predicted an age of "precision medicine" where patients are matched with drugs that target the specific genetic drivers ...
Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.
KalVista Pharmaceuticals saw its shares absolutely explode early on Tuesday after it was announced that the firm would be collaborating with Merck.
This could indicate that investors who seek to profit from falling equity prices are not currently targeting MRK. Over the last one-month, outflows of investor capital in ETFs holding MRK totaled $8.59 billion.
Roche's immunotherapy drug Tecentriq has lost market share to Merck & Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer. Many modern cancer drugs are approved on the basis of alternative clinical endpoints, such as tumour shrinkage or reduced risk of disease progression, but extending patients' lives remains the most important benchmark for oncologists. Latest data show Tecentriq's share of the bladder cancer market has slipped to 32 percent from around 45 percent before May's surprise clinical trial failure, according to an analysis on Thursday by Barclays analysts.
Global Healthcare Investment Advisors LLC wants to generate more than just healthy financial returns with its deals. The New York-based firm, which does business as the Global Health Investment Fund, also ...
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Merck & Co., Inc. with the following peers – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Roche Holding Ltd Genusssch., Novartis AG Sponsored ADR and Amgen Inc. ... Read more (Read more...)